The Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer

[1]  J. de Boniface,et al.  Survival After Breast Conservation vs Mastectomy Adjusted for Comorbidity and Socioeconomic Status , 2021, JAMA surgery.

[2]  R. Tamimi,et al.  Surgical Treatment After Neoadjuvant Systemic Therapy in Young Women With Breast Cancer , 2020, Annals of surgery.

[3]  M. Morrow,et al.  How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery? , 2020, Annals of Surgical Oncology.

[4]  E. Brogi,et al.  Selecting Node-Positive Patients for Axillary Downstaging with Neoadjuvant Chemotherapy , 2020, Annals of Surgical Oncology.

[5]  David L Rimm,et al.  Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. , 2020, Archives of pathology & laboratory medicine.

[6]  H. Rugo,et al.  Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial. , 2020, JAMA surgery.

[7]  Zhongtao Zhang,et al.  Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis , 2019, BMC Cancer.

[8]  Heikki Joensuu,et al.  Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.

[10]  Tanja Fehm,et al.  BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Bani,et al.  BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients , 2018, Breast Cancer Research and Treatment.

[12]  David Evans,et al.  Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study , 2018, The Lancet. Oncology.

[13]  T. Nielsen,et al.  Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. , 2017, Seminars in cancer biology.

[14]  P. Fasching,et al.  Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial , 2017, JAMA oncology.

[15]  G. Plitas,et al.  Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer , 2017, Annals of Surgical Oncology.

[16]  H. Burstein,et al.  Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  D. Berry,et al.  Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance) , 2016, Breast Cancer Research and Treatment.

[18]  R. Tamimi,et al.  BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer. , 2016, JAMA oncology.

[19]  C. Villarreal-Garza,et al.  Real-world outcomes in young women with breast cancer treated with neoadjuvant chemotherapy , 2016, Breast Cancer Research and Treatment.

[20]  D. Berry,et al.  Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). , 2015, Annals of surgery.

[21]  A. Schneeweiss,et al.  Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials , 2015, Breast Cancer Research and Treatment.

[22]  Brigitte Rack,et al.  Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  M. Brackstone,et al.  Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  K. Hunt,et al.  Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: Findings From the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial , 2014, Annals of surgery.

[26]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[27]  S. Mclaughlin,et al.  Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. , 2013, JAMA.

[28]  T. Fehm,et al.  Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. , 2013, The Lancet. Oncology.

[29]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Marks,et al.  Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  G. Vlastos,et al.  Recent increase of breast cancer incidence among women under the age of forty , 2007, British Journal of Cancer.

[32]  A. Luini,et al.  Very young women (<35 years) with operable breast cancer: features of disease at presentation. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  P. Andersen,et al.  Factors influencing the effect of age on prognosis in breast cancer: population based study , 2000, BMJ : British Medical Journal.

[34]  I Persson,et al.  The relation between survival and age at diagnosis in breast cancer. , 1986, The New England journal of medicine.

[35]  P. Fasching,et al.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. , 2018, The Lancet. Oncology.

[36]  Jama Oncology.  BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer , 2016 .

[37]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.